Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Ying-Qing Wang, Pingyuan Wang, Yu-Ting Wang, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 21, pp. 9575-9598
Closed Access | Times Cited: 201

Showing 26-50 of 201 citing articles:

Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation
Ahmed T. A. Boraei, Pankaj Kumar Singh, Mario Sechi, et al.
European Journal of Medicinal Chemistry (2019) Vol. 182, pp. 111621-111621
Closed Access | Times Cited: 62
Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA
Chéng Wáng, Lailiang Qu, Shang Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 17, pp. 12630-12650
Closed Access | Times Cited: 51
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 22
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
Limin Wang, Pingyuan Wang, X. T. Chen, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 3
Open Access | Times Cited: 21
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions
Denys Bondar, Yevgen Karpichev
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1269-1269
Open Access | Times Cited: 8
Design and synthesis of novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy
Norhan A. Abdelrahman, Ahmed A. Al‐Karmalawy, Maiy Y. Jaballah, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 3, pp. 981-997
Closed Access | Times Cited: 6
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies
Kalen Rimar, Phuoc T. Tran, Richard S. Matulewicz, et al.
Cancer (2017) Vol. 123, Iss. 11, pp. 1912-1924
Open Access | Times Cited: 61
Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy
Zigao Yuan, Shaopeng Chen, Changjun Chen, et al.
European Journal of Medicinal Chemistry (2017) Vol. 138, pp. 1135-1146
Closed Access | Times Cited: 59
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials
Bo Yuan, Na Ye, Shan-shan Song, et al.
Cancer Letters (2016) Vol. 386, pp. 47-56
Closed Access | Times Cited: 55
ADP-ribosylation: from molecular mechanisms to human disease
Nícolas C. Hoch, Luis Mariano Polo
Genetics and Molecular Biology (2019) Vol. 43, Iss. 1 suppl 1
Open Access | Times Cited: 54
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy
Junwei Wang, Hui Li, Guangchao He, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 1, pp. 122-139
Closed Access | Times Cited: 54
Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a “joint action” mode toward DNA
Xiaodong Qin, Lei Fang, Feihong Chen, et al.
European Journal of Medicinal Chemistry (2017) Vol. 137, pp. 167-175
Closed Access | Times Cited: 50
Conformational control in structure-based drug design
Ya‐Jun Zheng, Colin M. Tice, Suresh B. Singh
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 13, pp. 2825-2837
Closed Access | Times Cited: 49
Design, synthesis andin silicostudies of new quinazolinone derivatives as antitumor PARP-1 inhibitors
Sayed K. Ramadan, Eman Z. Elrazaz, Khaled A. M. Abouzid, et al.
RSC Advances (2020) Vol. 10, Iss. 49, pp. 29475-29492
Open Access | Times Cited: 48
Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors
Xuxing Chen, Xia‐Juan Huan, Qiufeng Liu, et al.
European Journal of Medicinal Chemistry (2018) Vol. 145, pp. 389-403
Closed Access | Times Cited: 47
DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
Mohammad Mirza‐Aghazadeh‐Attari, Caspian Ostadian, Amir Ata Saei, et al.
DNA repair (2019) Vol. 80, pp. 59-84
Closed Access | Times Cited: 45
A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes
Federica Guarra, Alessandro Pratesi, Chiara Gabbiani, et al.
Journal of Inorganic Biochemistry (2021) Vol. 217, pp. 111355-111355
Open Access | Times Cited: 38
Targeting the DNA Damage Response for Cancer Therapy
Ruoxi Wang, Yating Sun, Chunshuang Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15907-15907
Open Access | Times Cited: 16
Counteracting antibiotic resistance enzymes and efflux pumps
Meng Zheng, Tania J. Lupoli
Current Opinion in Microbiology (2023) Vol. 75, pp. 102334-102334
Closed Access | Times Cited: 13
Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity
Jie Zhou, Ming Ji, Haiping Yao, et al.
Organic & Biomolecular Chemistry (2018) Vol. 16, Iss. 17, pp. 3189-3202
Closed Access | Times Cited: 43
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity
Sean W. Reilly, Laura N. Puentes, Khadija Wilson, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 12, pp. 5367-5379
Open Access | Times Cited: 41
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Nur Aininie Yusoh, Haslina Ahmad, Martin R. Gill
ChemMedChem (2020) Vol. 15, Iss. 22, pp. 2121-2135
Open Access | Times Cited: 37
Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicity
Huadong Chen, Chuan‐Huizi Chen, Yuting Wang, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 3, pp. 714-727
Open Access | Times Cited: 36
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515
Gianluca Papeo, Paolo Orsini, Nilla Avanzi, et al.
ACS Medicinal Chemistry Letters (2019) Vol. 10, Iss. 4, pp. 534-538
Open Access | Times Cited: 36
Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-κB Signaling Pathway
Shu-Yuan Ni, Xinglong Zhong, Ze-Hua Li, et al.
Cardiovascular Toxicology (2020) Vol. 20, Iss. 5, pp. 482-491
Closed Access | Times Cited: 36

Scroll to top